Skip to main content

Table 1 Baseline characteristics of 26 randomized controlled trials in the meta-analysis (number = 14,060)

From: Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis

Authors/year/phase Histology Patients enrolled Treatment aim Median age, years Median duration, weeks Median PFS, m Median OS, m Number for analysis Severe infections Reported infectious events
Burtness B. et al ./2005/III Head and neck cancer 117 Cetuximab + DDP 60.6 4.5 4.2 9.2 58 15 Infections
    Placebo + DDP 58.3 3 2.7 8 58 10
Bonner J.A . et al ./2006/III Head and neck cancer 424 Cetuximab + radiotherapy 56 8 24.4 49 208 1 Infections
    Radiotherapy 58 NR 14.9 29.3 212 1
Jonker D. J. et al ./2007/III CRC 572 Cetuximab + BSC 63 8.1 NR 6.1 288 37 Infections
    BSC 63.6 NR NR 4.6 274 15
Borner M. et al ./2008/II CRC 74 Cetuximab + oxaliplatin + capecitabine 60 18 7.2 20.5 37 0 Febrile neutropenia
    Oxaliplatin + capecitabine 63 18 5.8 16.5 37 0
Rosell R. et al ./2008/II NSCLC 86 Cetuximab + NVB + DDP 58 13.6 5 8.3 42 7 Infections
    NVB + DDP 57 12 4.6 7.3 43 2
Sobrero A.F. et al ./2008/III CRC 1298 Cetuximab + irinotecan 61 14 4 10.7 638 49 Febrile neutropenia
    Irinotecan 62 13.1 2.6 10 629 39
Vermorken J.B. et al. /2008/III Head and neck cancer 422 Cetuximab + platinum + FU 56 18 5.6 10.1 219 28 Febrile neutropenia, pneumonia, sepsis
    Platinum + FU 57 15 3.3 7.4 215 15
Lienbaum R. et al ./2009/II NSCLC 64 Cetuximab + PTX NR 16 3.4 NR 30 1 Infections
    Bortezomib + PTX NR 8 1.9 NR 29 1
Pirker R. et al ./2009/III NSCLC 1125 Cetuximab + NVB + DDP 59 18 NR 11.3 548 129 Febrile neutropenia, sepsis
    NVB + DDP 60 14 NR 10.1 562 90
Tol J. et al ./2009/III CRC 755 Cetuximab + capecitabine + oxaliplatin + Bev 62 30 10.7 20.3 366 22 Infections
    Capecitabine + oxaliplatin + Bev 62 25.7 9.4 19.4 366 25
Lynch T.J. et al ./2010/III NSCLC 676 Cetuximab + chemotherapy 64 13 4.4 9.69 325 15 Febrile neutropenia
    Chemotherapy 65 12 4.24 8.38 320 11
Govindan R. et al ./2011/II NSCLC 101 Cetuximab + chemoradiotherapy 66 NR 12.3 22.2 53 9 Febrile neutropenia, pneumonia,
    Chemoradiotherapy 65 NR 12.6 22.4 50 10
Alberts S.R. et al ./2012/III CRC 2686 Cetuximab + FOLFOX NR NR NR NR 931 96 Infections, febrile neutropenia, pneumonia
    FOLFOX NR NR NR NR 894 45
Dewdney A. et al ./2012/II CRC 165 Cetuximab + capecitabine + oxaliplatin + radiotherapy 65 NR NR NR 83 1 Febrile neutropenia
    Capecitabine + oxaliplatin + radiotherapy 61 NR NR NR 81 1
Saltz L. et al ./2012/III CRC 247 Cetuximab + Bev + FOLFOX 63.2 NR 8.3 19.5 121 1 Sepsis
    Bev + FOLFOX 61.2 NR 11 21.3 118 1
Baselga J. et al ./2013/II MBC 181 Cetuximab + DDP 53 13.6 3.7 12.9 114 2 Sepsis
    DDP 52 13.1 1.5 9.4 57 0
Kim E.S. et al ./2013/III NSCLC 605 Cetuximab + Pemetrexed 64 NR 2.9 6.9 292 35 Infections, lung infections, sepsis
    Pemetrexed 65 NR 2.8 7.8 289 23
Burtness B. et al ./2014/II Pancreatic cancer 87 Cetuximab + Doc + irinotecan 60 16.5 4.5 6.5 45 5 Febrile neutropenia, infections
    Doc + irinotecan 60 14.5 3.9 5.3 46 4
Huang J. et al ./2014/III CRC 146 Cetuximab + FOLFIRI 57 NR NR NR 40 3 Infections, febrile neutropenia
    FOLFIRI 59 NR NR NR 106 3
Hussain M. et al ./2014/II Urothelial carcinoma 88 Cetuximab + GEM + DDP 60.9 21.4 7.6 14.3 59 7 Infections, pneumonia
    GEM + DDP 65.8 21.4 8.5 17.4 28 3
van den Heuval M.M. et al. /2014/II NSCLC 102 Cetuximab + chemoradiotherapy 62 NR NR NR 51 3 Pneumonia
    Chemoradiotherapy 63 NR NR NR 51 0
Douillard J.Y. et al ./2010/III CRC 1183 Panitumumab + FOLFOX4 NR 20 9.6 23.9 539 15 Febrile neutropenia
    FOLFOX4 NR NR 8.6 19.7 545 14
Peeters M. et al./ 2010/III CRC 1186 Panitumumab + FOLFIRI NR NR 5.9 14.5 539 9 Febrile neutropenia
    FOLFIRI NR NR 3.9 12.5 540 16
Seymour M. T. et al ./2013/III CRC 460 Panitumumab + irinotecan 64 12 NR 10.4 219 42 Infections
    Irinotecan 63 12 NR 10.5 218 22
Vermorken J.B. et al ./2008/III Head and neck cancer 657 Panitumumab + DDP + FU 58 18.3 5.8 11.1 325 20 Febrile neutropenia
    DDP + FU 59 NR 4.6 9 325 17
Waddell T. et al ./2013/III Esophagogastric cancer 553 Panitumumab + epirubicin + oxaliplatin + capecitabine 63 15 7.4 8.8 276 48 Infection, febrile neutropenia
    Epirubicin + oxaliplatin + capecitabine 62 15 6 11.3 266 70
  1. Bev, bevacizumab; BSC, best support care; CRC, colorectal cancer; DDP, cisplatin; Doc, docetaxel; FOLFIRI, folinic acid (leucovorin), fluorouracil and irinotecan; FOLFOX, folinic acid (leucovorin), fluorouracil and oxaliplatin; Fu, fluorouracil; MBC, metastatic breast cancer; NR, not reported; NSCLC, non-small-cell lung cancer; NVB, vinorelbine; OS, overall survival; PTX, paclitaxel; PFS, progression free survival.